Establishment of Reporter Lines for Detecting Fragile X Mental Retardation (FMR1) Gene Reactivation in Human Neural Cells

Stem Cells

Volumn 35, Issue 1, 2017, Pages 158-169

  Li, Meng ^a   Zhao, Huashan ^a   Ananiev, Gene E ^b   Musser, Michael T ^a   Ness, Kathryn H ^a   Maglaque, Dianne L ^a   Saha, Krishanu ^b,c   Bhattacharyya, Anita ^a   Zhao, Xinyu ^a,d  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c University of Wisconsin Madison   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Drug discovery; FMR1; FMRP; Fragile X syndrome; High throughput; Induced pluripotent stem cells; Luciferase

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN; GENOMIC DNA; LUCIFERASE; MESSENGER RNA; NESTIN; TRANSCRIPTION FACTOR PAX6; AZACITIDINE; NANOPARTICLE;

ARTICLE; CELL CULTURE; CELL DENSITY; CONTROLLED STUDY; CRISPR CAS SYSTEM; ENZYME ACTIVITY; GENE ACTIVATION; GENE EDITING; GENE EXPRESSION; GENE LOCUS; GENE SILENCING; GENETIC MANIPULATION; GENETIC SCREENING; GENOMIC INSTABILITY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; INDUCED PLURIPOTENT STEM CELL; MOLECULAR LIBRARY; NERVE CELL DIFFERENTIATION; NEURAL STEM CELL; POINT MUTATION; PROTEIN EXPRESSION; STOP CODON; CELL DIFFERENTIATION; CELL LINE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; GENETICS; METABOLISM; NERVE CELL; PHARMACOLOGY; PLURIPOTENT STEM CELL; REPORTER GENE; TRANSCRIPTION INITIATION;

AZACITIDINE; CELL DIFFERENTIATION; CELL LINE; FRAGILE X MENTAL RETARDATION PROTEIN; GENES, REPORTER; HUMANS; LUCIFERASES; NANOPARTICLES; NEURAL STEM CELLS; NEURONS; PLURIPOTENT STEM CELLS; SMALL MOLECULE LIBRARIES; TRANSCRIPTIONAL ACTIVATION;

EID: 84979650434     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.2463     Document Type: Article

References (48)

1. Coffee B, Keith K, Albizua I et al. Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. Am J Hum Genet 2009;85:503–514.
2. Hagerman RJ Hagerman PJ. Fragile X Syndrome. Baltimore MD: Johns Hopkins University Press, 2002.
3. Cohen IL, Sudhalter V, Pfadt A et al. Why are autism and the fragile-X syndrome associated? Conceptual and methodological issues. AmJHumGenet 1991;48:195–202.
4. Fisch GS, Cohen IL, Wolf EG et al. Autism and the fragile X syndrome. Am J Psychiatry 1986;143:71–73.
5. Hagerman RJ, Ono MY Hagerman PJ. Recent advances in fragile X: A model for autism and neurodegeneration. Curr Opin Psychiatry 2005;18:490–496.
6. Kaufmann WE, Cortell R, Kau AS et al. Autism spectrum disorder in fragile X syndrome: Communication, social interaction, and specific behaviors. Am J Med Genet A 2004;129:225–234.
7. Reiss AL, Feinstein C Rosenbaum KN. Autism and genetic disorders. Schizophr Bull 1986;12:724–738.
8. Hatton DD, Sideris J, Skinner M et al. Autistic behavior in children with fragile X syndrome: Prevalence, stability, and the impact of FMRP. Am J Med Genet A 2006;140A:1804–1813.
9. Lathe R. Fragile X and autism. Autism 2009;13:194–197.
10. Brouwer JR, Mientjes EJ, Bakker CE et al. Elevated Fmr1 mRNA levels and reduced protein expression in a mouse model with an unmethylated fragile X full mutation. Exp Cell Res 2007;313:244–253.
11. Loesch DZ, Huggins R, Hay DA et al. Genotype-phenotype relationships in fragile X syndrome: A family study. Am J Hum Genet 1993;53:1064–1073.
12. Loesch DZ, Huggins RM Hagerman RJ. Phenotypic variation and FMRP levels in fragile X. Ment Retard Dev Disabil Res Rev 2004;10:31–41.
13. Hagerman RJ, Hull CE, Safanda JF et al. High functioning fragile X males: Demonstration of an unmethylated fully expanded FMR-1 mutation associated with protein expression. Am J Med Genet 1994;51:298–308.
14. Loesch D, Hagerman R. Unstable mutations in the FMR1 gene and the phenotypes. Adv Exp Med Biol 2012;769:78–114.
15. Smeets HJ, Smits AP, Verheij CE et al. Normal phenotype in two brothers with a full FMR1 mutation. Hum Mol Genet 1995;4:2103–2108.
16. Pietrobono R, Tabolacci E, Zalfa F et al. Molecular dissection of the events leading to inactivation of the FMR1 gene. Hum Mol Genet 2005;14:267–277.
17. Tabolacci E, De Pascalis I, Accadia M et al. Modest reactivation of the mutant FMR1 gene by valproic acid is accompanied by histone modifications but not DNA demethylation. Pharmacogenet Genomics 2008;18:738–741.
18. Gholizadeh S, Arsenault J, Xuan ICY et al. Reduced phenotypic severity following Adeno-associated Virus-mediated Fmr1 gene delivery in fragile X Mice. Neuropsychopharmacology 2014;39:3100–3111.
19. Musumeci SA, Calabrese G, Bonaccorso CM et al. Audiogenic seizure susceptibility is reduced in fragile X knockout mice after introduction of FMR1 transgenes. Exp Neurol 2007;203:233–240.
20. Paylor R, Yuva-Paylor LA, Nelson DL et al. Reversal of sensorimotor gating abnormalities in Fmr1 knockout mice carrying a human Fmr1 transgene. Behav Neurosci 2008;122:1371–1377.
21. Peier AM, McIlwain KL, Kenneson A et al. (over)correction of FMR1 deficiency with YAC transgenics: Behavioral and physical features. Hum Mol Genet 2000;9:1145–1159.
22. Zeier Z, Kumar A, Bodhinathan K et al. Fragile X mental retardation protein replacement restores hippocampal synaptic function in a mouse model of fragile X syndrome. Gene Ther 2009;16:1122–1129.
23. Guo W, Allan AM, Zong R et al. Ablation of fmrp in adult neural stem cells disrupts hippocampus-dependent learning. Nat Med 2011;17:559–565.
24. Pietrobono R, Pomponi MG, Tabolacci E et al. Quantitative analysis of DNA demethylation and transcriptional reactivation of the FMR1 gene in fragile X cells treated with 5-azadeoxycytidine. Nucleic Acids Res 2002;30:3278–3285.
25. Chiurazzi P, Pomponi MG, Willemsen R et al. In vitro reactivation of the FMR1 gene involved in fragile X syndrome. Hum Mol Genet 1998;7:109–113.
26. Kumari D, Bhattacharya A, Nadel J et al. Identification of fragile X syndrome-specific molecular markers in human fibroblasts: A useful model to test the efficacy of therapeutic Drugs. Human Mutation 2014;35:1485–1494.
27. Brendel C, Mielke B, Hillebrand M et al. Methotrexate treatment of FraX fibroblasts results in FMR1 transcription but not in detectable FMR1 protein levels. J Neurodev Disord 2013;5:23.
28. Doers ME, Musser MT, Nichol R et al. iPSC-derived forebrain neurons from FXS individuals show defects in initial neurite outgrowth. Stem Cells Dev 2014;23:1777–1787.
29. de Esch CE, Ghazvini M, Loos F et al. Epigenetic characterization of the FMR1 promoter in induced pluripotent stem cells from human fibroblasts carrying an unmethylated full Mutation. Stem Cell Rep 2014;3:548–555.
30. Halevy T, Czech C Benvenisty N. Molecular mechanisms regulating the defects in fragile X syndrome neurons derived from human pluripotent stem Cells. Stem Cell Rep 2015;4:37–46.
31. Brick DJ, Nethercott HE, Montesano S et al. The autism spectrum disorders stem cell resource at children's hospital of orange county: implications for disease modeling and drug discovery. Stem Cells Transl Med 2014;3:1275–1286.
32. Bhattacharyya A, Zhao Xl. Human pluripotent stem cell models of Fragile X syndrome. Mol Cell Neurosci 2016;73:43–51.
33. Sheridan SD, Theriault KM, Reis SA et al. Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome. PLoS One 2011;6:e26203.
34. Kaufmann M, Schuffenhauer A, Fruh I et al. High-throughput screening using iPSC-derived neuronal progenitors to identify compounds counteracting epigenetic gene silencing in fragile X Syndrome. J Biomol Screening 2015;20:1101–1111.
35. Bar-Nur O, Caspi I Benvenisty N. Molecular analysis of FMR1 reactivation in fragile-X induced pluripotent stem cells and their neuronal derivatives. J Mol Cell Biol 2012;4:180–183.
36. Urbach A, Bar-Nur O, Daley GQ et al. Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem Cells. Cell Stem Cell 2010;6:407–411.
37. Schadt EE, Buchanan S, Brennand KJ et al. Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders. Front Pharmacol 2014;5:252.
38. Kumari D, Swaroop M, Southall N et al. High-throughput screening to identify compounds that increase fragile X mental retardation protein expression in neural stem cells differentiated from fragile X syndrome patient-derived induced pluripotent stem Cells. Stem Cells Transl Med 2015;4:800–808.
39. Zhang F, Wen Y, Guo X. CRISPR/Cas9 for genome editing: progress, implications and challenges. Hum Mol Genet 2014;23:R40–R46.
40. Chambers SM, Fasano CA, Papapetrou EP et al. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 2009;27:275–280.
41. Zhang JH, Chung TD Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening Assays. J Biomol Screening 1999;4:67–73.
42. Kim JH, Lee SR, Li LH et al. High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice. PLoS One 2011;6:e18556.
43. Pretto DI, Eid JS, Yrigollen CM et al. Differential increases of specific FMR1 mRNA isoforms in premutation carriers. J Med Genet 2015;52:42–52.
44. Barkess G West AG. Chromatin insulator elements: establishing barriers to set heterochromatin boundaries. Epigenomics 2012;4:67–80.
45. Guo W, Murthy AC, Zhang L et al. Inhibition of GSK3beta improves hippocampus-dependent learning and rescues neurogenesis in a mouse model of fragile X syndrome. Hum Mol Genet 2012;21:681–691.
46. Chiurazzi P, Pomponi MG, Pietrobono R et al. Synergistic effect of histone hyperacetylation and DNA demethylation in the reactivation of the FMR1 gene. Hum Mol Genet 1999;8:2317–2323.
47. Coffee B, Zhang F, Warren ST et al. Acetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells. Nat Genet 1999;22:98–101.
48. Coffee B, Zhang F, Ceman S et al. Histone modifications depict an aberrantly heterochromatinized FMR1 gene in fragile x syndrome. Am J Hum Genet 2002;71:923–932.